MAIA Biotechnology Granted European Patent for Next Generation Telomere-Targeting Agents for Cancer Therapy
MAIA Biotechnology (NYSE American: MAIA) has been granted a European patent for its portfolio of ateganosine-based analogues targeting cancer therapy. The patent covers mercaptopurine ribonucleoside analogues that function as cancer-fighting immunosuppressive agents, disrupting telomere structure and reducing immune system activity to combat cancer cell growth.
The technology, invented by MAIA's CSO Dr. Sergei Gryaznov and Scientific Advisory Board member Dr. Jerry Shay, represents a significant advancement in telomere-targeting compounds with potentially improved cancer cell specificity. The company's global IP portfolio now includes 10 issued patents worldwide, with European validation in 19 countries, and 24 pending patent applications.
MAIA Biotechnology (NYSE American: MAIA) ha ottenuto un brevetto europeo per il suo portafoglio di analoghi a base di ateganosina destinati alla terapia oncologica. Il brevetto copre analogi del ribonucleoside della mercaptopurina che agiscono come agenti immunosoppressivi antitumorali, alterando la struttura dei telomeri e riducendo l'attivit脿 del sistema immunitario per contrastare la crescita delle cellule cancerose.
La tecnologia, inventata dal CSO di MAIA, Dr. Sergei Gryaznov, e dal membro del Comitato Scientifico, Dr. Jerry Shay, rappresenta un importante progresso nei composti che mirano ai telomeri, con una potenziale maggiore selettivit脿 per le cellule tumorali. Il portafoglio di propriet脿 intellettuale globale dell'azienda comprende ora 10 brevetti concessi nel mondo, con validazione europea in 19 paesi, e 24 domande di brevetto in corso.
MAIA Biotechnology (NYSE American: MAIA) ha obtenido una patente europea para su cartera de an谩logos a base de ateganosina dirigidos a la terapia contra el c谩ncer. La patente cubre an谩logos del ribonucle贸sido de mercaptopurina que act煤an como agentes inmunosupresores antitumorales, alterando la estructura de los tel贸meros y disminuyendo la actividad del sistema inmunitario para combatir el crecimiento de las c茅lulas cancerosas.
La tecnolog铆a, inventada por el CSO de MAIA, Dr. Sergei Gryaznov, y por el miembro del Consejo Asesor Cient铆fico, Dr. Jerry Shay, representa un avance significativo en compuestos que apuntan a los tel贸meros, con una posible mayor especificidad hacia las c茅lulas cancerosas. La cartera global de propiedad intelectual de la compa帽铆a incluye ahora 10 patentes concedidas en todo el mundo, con validaci贸n europea en 19 pa铆ses, y 24 solicitudes de patente pendientes.
MAIA Biotechnology (NYSE American: MAIA)電� 頃晹 旃橂毳� 氇╉憸搿� 頃橂姅 鞎勴厡臧�雲胳嫚 旮半皹 鞙犾偓觳� 韽姼韽措Μ鞓れ棎 雽�頃� 鞙犽熃 韸鬼棃毳� 須嶋摑頄堨姷雼堧嫟. 鞚� 韸鬼棃電� 韰旊氙胳柎 甑“毳� 甑愲瀫頃橁碃 鞎旍劯韽� 靹膘灔鞚� 鞏奠牅頃橁赴 鞙勴暣 氅挫棴瓿� 頇滊彊鞚� 臧愳唽鞁滍偆電� 毹胳簠韱犿摠毽� 毽炒雺错伌霠堨槫靷澊霌� 鞙犾偓觳�毳� 頃晹 鞛戩毄鞚� 頃橂姅 氅挫棴鞏奠牅鞝滊 攴滌爼頃╇媹雼�.
鞚� 旮办垹鞚� MAIA鞚� CSO鞚� Dr. Sergei Gryaznov鞕赌 瓿柬暀鞛愲鞙勳洂須� 鞙勳洂鞚� Dr. Jerry Shay臧� 氚滊獏頄堨溂氅�, 韰旊氙胳柎毳� 響滌爜頃橂姅 頇旐暕氍� 攵勳暭鞐愳劀 鞎旍劯韽棎 雽�頃� 靹犿儩靹膘澊 頄レ儊霅� 臧�電レ劚鞚� 鞛堧姅 欷戩殧頃� 歆勳爠鞛呺媹雼�. 須岇偓鞚� 旮�搿滊矊 歆�鞁濎灛靷� 韽姼韽措Μ鞓る姅 順勳灛 鞙犽熃 19臧滉淡鞐愳劀 須牓鞚� 鞚胳爼霅� 鞝� 靹戈硠 10瓯挫潣 霌彪 韸鬼棃鞕赌 於滌洂 欷戩澑 韸鬼棃 24瓯�鞚� 韽暔頃橁碃 鞛堨姷雼堧嫟.
MAIA Biotechnology (NYSE American: MAIA) s'est vu d茅livrer un brevet europ茅en pour son portefeuille d'analogues 脿 base d'ateganosine destin茅s 脿 la th茅rapie anticanc茅reuse. Le brevet couvre des analogues du ribonucl茅oside de mercaptopurine qui agissent comme agents immunosuppresseurs anticanc茅reux, perturbant la structure des t茅lom猫res et r茅duisant l'activit茅 du syst猫me immunitaire pour lutter contre la croissance des cellules canc茅reuses.
La technologie, invent茅e par le CSO de MAIA, le Dr Sergei Gryaznov, et par le membre du conseil consultatif scientifique, le Dr Jerry Shay, repr茅sente une avanc茅e significative dans les compos茅s ciblant les t茅lom猫res, avec une sp茅cificit茅 potentiellement am茅lior茅e pour les cellules canc茅reuses. Le portefeuille mondial de propri茅t茅 intellectuelle de la soci茅t茅 comprend d茅sormais 10 brevets d茅livr茅s dans le monde, avec une validation europ茅enne dans 19 pays, et 24 demandes de brevet en attente.
MAIA Biotechnology (NYSE American: MAIA) wurde ein europ盲isches Patent f眉r sein Portfolio an auf ateganosin basierenden Analoga zur Krebstherapie erteilt. Das Patent umfasst Mercaptopurin-Ribonukleosid-Analoga, die als krebsbek盲mpfende immunsuppressive Wirkstoffe wirken, die Telomerstruktur st枚ren und die Immunaktivit盲t verringern, um das Wachstum von Krebszellen zu bek盲mpfen.
Die Technologie, erfunden von MAIAs CSO Dr. Sergei Gryaznov und dem Mitglied des Wissenschaftlichen Beirats Dr. Jerry Shay, stellt einen bedeutenden Fortschritt bei telomergerichteten Verbindungen dar, mit m枚glicherweise verbesserter Selektivit盲t gegen眉ber Krebszellen. Das globale IP-Portfolio des Unternehmens umfasst nun 10 erteilte Patente weltweit, mit europ盲ischer Validierung in 19 L盲ndern, und 24 anh盲ngigen Patentanmeldungen.
- New European patent strengthens IP protection for telomere-targeting cancer therapy
- Technology shows potential for improved cancer cell targeting specificity
- Extensive patent portfolio with 10 issued patents and 24 pending applications
- Patent coverage extends across 19 European countries
- None.
Insights
MAIA strengthens its IP position in Europe with a key patent for its telomere-targeting cancer therapy platform.
This European patent grant represents a significant intellectual property milestone for MAIA Biotechnology's cancer treatment platform. The patent broadly covers ateganosine-based analogues for telomere-targeting anticancer therapy and methods for using ateganosine (THIO) alone or in combination with checkpoint inhibitors.
The technology is particularly noteworthy as it targets telomeres - the protective caps at chromosome ends that play a crucial role in cancer cell immortality. By disrupting telomere structure and function, these mercaptopurine nucleoside analogues can potentially trigger programmed cancer cell death while modulating immune system activity.
From an IP perspective, this patent strengthens MAIA's position across 19 European countries, complementing their existing portfolio of 10 issued patents worldwide and 24 pending applications. For a clinical-stage biotech company, robust patent protection is essential for preserving market exclusivity and future commercialization potential.
The inventors behind this technology include the company's Chief Scientific Officer and a Scientific Advisory Board member, highlighting the internal innovation capabilities of MAIA. Their focus on developing next-generation compounds with "improved specificity towards cancer cells relative to normal cells" suggests potential advantages over existing treatments in terms of efficacy and safety profiles.
This patent grant enhances MAIA's competitive position in the telomere-targeting therapeutic space and potentially increases the company's attractiveness for partnerships or licensing opportunities in the European market.
Cancer-fighting immunosuppressive agents shown to disrupt telomeres and suspend growth of cancer cells聽
CHICAGO , Aug. 13, 2025 (GLOBE NEWSWIRE) -- MAIA Biotechnology, Inc. (NYSE American: MAIA) (鈥淢AIA鈥�, the 鈥淐ompany鈥�), a clinical-stage biopharmaceutical company focused on developing targeted immunotherapies for cancer, today announced that the European Patent Office has decided to grant a patent broadly covering a portfolio of ateganosine-based analogues for telomere-targeting anticancer therapy and methods of using ateganosine (THIO) alone or before administration of checkpoint inhibitors (CPIs). The patent, titled 鈥淢ercaptopurine Ribonucleoside Analogues for Altering Telomerase Mediated Telomere,鈥� was invented by MAIA鈥檚 Chief Scientific Officer Sergei M. Gryaznov, PhD and Scientific Advisory Board member Jerry W. Shay, PhD.
鈥淢ercaptopurine nucleoside analogues are cancer-fighting immunosuppressive agents that disrupt the structure and function of telomeres and reduce immune system activity, interfering with the growth of cancer cells and causing programmed cancer cell death. As an important extension of MAIA鈥檚 innovative cancer treatment platform, these new compounds are key next-generation telomere-targeting agents with potentially improved specificity towards cancer cells relative to normal cells and with potentially increased anticancer activity,鈥� said Dr. Gryaznov.
鈥淭he new IP is expected to further secure and expand the value of our first-in-class telomere-targeting compounds across the European scientific community,鈥� added MAIA Chairman and CEO Vlad Vitoc, M.D.
MAIA鈥檚 global patent and patent-pending estate covers several areas including telomerase mediated telomere altering compounds and treatment of therapy-resistant cancers. Further, ateganosine鈥檚 immunogenic treatment strategy, which focuses on sequential combination with checkpoint inhibitors, has been filed worldwide. MAIA鈥檚 IP portfolio for ateganosine currently comprises 10聽issued patents worldwide including Europe (validated in 19 countries) along with 24聽pending patent applications.
About Ateganosine
Ateganosine (THIO, 6-thio-dG or 6-thio-2鈥�-deoxyguanosine) is a first-in-class investigational telomere-targeting agent currently in clinical development to evaluate its activity in non-small cell lung cancer (NSCLC). Telomeres, along with the enzyme telomerase, play a fundamental role in the survival of cancer cells and their resistance to current therapies. The modified nucleotide 6-thio-2鈥�-deoxyguanosine induces telomerase-dependent telomeric DNA modification, DNA damage responses, and selective cancer cell death. Ateganosine-damaged telomeric fragments accumulate in cytosolic micronuclei and activates both innate (cGAS/STING) and adaptive (T-cell) immune responses. The sequential treatment of ateganosine followed by PD-(L)1 inhibitors resulted in profound and persistent tumor regression in advanced, in vivo cancer models by induction of cancer type鈥搒pecific immune memory. Ateganosine is presently developed as a second or later line of treatment for NSCLC for patients that have progressed beyond the standard-of-care regimen of existing checkpoint inhibitors.
About MAIA Biotechnology, Inc.
MAIA is a targeted therapy, immuno-oncology company focused on the development and commercialization of potential first-in-class drugs with novel mechanisms of action that are intended to meaningfully improve and extend the lives of people with cancer. Our lead program is ateganosine (THIO), a potential first-in-class cancer telomere targeting agent in clinical development for the treatment of NSCLC patients with telomerase-positive cancer cells. For more information, please visit .
Forward Looking Statements
MAIA cautions that all statements, other than statements of historical facts contained in this press release, are forward-looking statements. Forward-looking statements are subject to known and unknown risks, uncertainties, and other factors that may cause our or our industry鈥檚 actual results, levels or activity, performance or achievements to be materially different from those anticipated by such statements. The use of words such as 鈥渕ay,鈥� 鈥渕ight,鈥� 鈥渨ill,鈥� 鈥渟hould,鈥� 鈥渃ould,鈥� 鈥渆xpect,鈥� 鈥減lan,鈥� 鈥渁nticipate,鈥� 鈥渂elieve,鈥� 鈥渆stimate,鈥� 鈥減roject,鈥� 鈥渋ntend,鈥� 鈥渇uture,鈥� 鈥減otential,鈥� or 鈥渃ontinue,鈥� and other similar expressions are intended to identify forward looking statements. However, the absence of these words does not mean that statements are not forward-looking. For example, all statements we make regarding (i) the initiation, timing, cost, progress and results of our preclinical and clinical studies and our research and development programs, (ii) our ability to advance product candidates into, and successfully complete, clinical studies, (iii) the timing or likelihood of regulatory filings and approvals, (iv) our ability to develop, manufacture and commercialize our product candidates and to improve the manufacturing process, (v) the rate and degree of market acceptance of our product candidates, (vi) the size and growth potential of the markets for our product candidates and our ability to serve those markets, and (vii) our expectations regarding our ability to obtain and maintain intellectual property protection for our product candidates, are forward looking. All forward-looking statements are based on current estimates, assumptions and expectations by our management that, although we believe to be reasonable, are inherently uncertain. Any forward-looking statement expressing an expectation or belief as to future events is expressed in good faith and believed to be reasonable at the time such forward-looking statement is made. However, these statements are not guarantees of future events and are subject to risks and uncertainties and other factors beyond our control that may cause actual results to differ materially from those expressed in any forward-looking statement. Any forward-looking statement speaks only as of the date on which it was made. We undertake no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future events or otherwise, except as required by law. In this release, unless the context requires otherwise, 鈥淢AIA,鈥� 鈥淐ompany,鈥� 鈥渨e,鈥� 鈥渙ur,鈥� and 鈥渦s鈥� refers to MAIA Biotechnology, Inc. and its subsidiaries.
Investor Relations Contact
+1 (872) 270-3518
FAQ
What patent did MAIA Biotechnology receive from the European Patent Office in 2025?
How do MAIA's mercaptopurine nucleoside analogues work in cancer treatment?
What is the current size of MAIA Biotechnology's patent portfolio?
Who are the inventors of MAIA's patented telomere-targeting technology?
What advantages does MAIA's new telomere-targeting technology offer?
